Using immunohistochemistry, Fritzche et al [28], showed that increased expression of ADAM9 in prostate cancer was significantly associated with shortened relapse-free survival as measured by increasing serum PSA levels. This evidence concerns the gene ADAM9 and Familial prostate cancer.